risks of glp 1 drugs mapping the effectiveness and The GLP-1 revolution: What UAB researchers are discovering about how these work Glucagon-like Receptor-1 agonists for obesity:

Prog Mol Biol Transl Sci 121: 23-65, 2014

Kinlen D, Cody D, OShea D

This includes: Structured dietary changes : Working with a dietitian to develop a sustainable, nutritionally balanced eating plan with an appropriate caloric deficit Regular physical activity : Gradually increasing to 150-300 minutes of moderate-intensity exercise weekly, as per UK Chief Medical Officers' guidelines Behavioural support : Accessing psychological interventions or NHS Talking Therapies to address eating behaviours and maintain motivation Regular monitoring : Attending follow-up appointments to assess weight loss progress, tolerability, and any emerging health concerns Patients should discuss any desire to use additional weight loss products with their healthcare team, who can provide evidence-based guidance tailored to individual circumstances

Zachary Burns is a family medicine physician at the University of Rochester Medical Center, Associate Director of Moving Medicine Forward, and a partner of RLMI

His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs

NK, RP, SL, and LA wrote the manuscript, and all authors critically revised it